Paul Wallace Ph.D. has been appointed chief business officer at MISSION Therapeutics. Dr. Wallace will be responsible for the future business strategy for the company’s pipeline, exploring strategic options such as development partnerships.
 
Dr. Wallace has 20 years of business development experience and most recently served as executive vice president and head of business development at Medivir AB, and was a member of the executive management team. He was responsible for strategic and operational leadership, R&D portfolio management and investment planning. 
 
Anker Lundemose, MISSION chief executive officer, said, “With MISSION currently embarking on the preclinical development of its lead molecules, Paul’s extensive business development experience will be invaluable in helping us find the right strategic partnerships to fully realize the potential of these assets. Our core focus is cancer, but our platform discovery approach has yielded highly promising molecules for other indications, such as Parkinson’s disease. We see partnering as an attractive option for taking these non-core projects forward.”